(Q57268167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

Clarisa Beatriz Palatnik-de-Sousa

29 December 2019

main subject

visceral leishmaniasis

1 reference

Quillaja saponaria

1 reference

based on heuristic

inferred from title

author

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

Luzineide Wanderley Tinoco

29 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

José Paz Parente

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Santos WR

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Casas CP

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Paraguai de Souza E

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

da Silva BP

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Palatnik M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

2470-2479

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Recent advances in veterinary vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

QS-21 structure/function studies: effect of acylation on adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Covalent chemical events in immune induction: fundamental and therapeutic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Haemolytic time course differences between steroid and triterpenoid saponins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.072

10.1016/J.VACCINE.2004.01.072

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15193411%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference